| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | tolcapone (Tasmar®) |
| Formulation | 100 mg film-coated tablet |
| Reference number | 312 |
| Indication | In combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who failed to respond to or are intolerant of other Catechol-O-methyltransferase (COMT) inhibitors |
| Company | Meda Pharmaceuticals Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 15/03/2005 |